Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer.
Blasco-Benito S, Moreno E, Seijo-Vila M, Tundidor I, Andradas C, Caffarel MM, Caro-Villalobos M, Urigüen L, Diez-Alarcia R, Moreno-Bueno G, Hernández L, Manso L, Homar-Ruano P, McCormick PJ, Bibic L, Bernadó-Morales C, Arribas J, Canals M, Casadó V, Canela EI, Guzmán M, Pérez-Gómez E, Sánchez C. Blasco-Benito S, et al. Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3863-3872. doi: 10.1073/pnas.1815034116. Epub 2019 Feb 7. Proc Natl Acad Sci U S A. 2019. PMID: 30733293 Free PMC article.
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J. Matar P, et al. Clin Cancer Res. 2004 Oct 1;10(19):6487-501. doi: 10.1158/1078-0432.CCR-04-0870. Clin Cancer Res. 2004. PMID: 15475436
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.
Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J. Rodriguez-Pinilla SM, et al. Mod Pathol. 2007 Apr;20(4):474-81. doi: 10.1038/modpathol.3800760. Epub 2007 Mar 2. Mod Pathol. 2007. PMID: 17334350 Free article.
Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.
Pérez-Gómez E, Andradas C, Blasco-Benito S, Caffarel MM, García-Taboada E, Villa-Morales M, Moreno E, Hamann S, Martín-Villar E, Flores JM, Wenners A, Alkatout I, Klapper W, Röcken C, Bronsert P, Stickeler E, Staebler A, Bauer M, Arnold N, Soriano J, Pérez-Martínez M, Megías D, Moreno-Bueno G, Ortega-Gutiérrez S, Artola M, Vázquez-Villa H, Quintanilla M, Fernández-Piqueras J, Canela EI, McCormick PJ, Guzmán M, Sánchez C. Pérez-Gómez E, et al. J Natl Cancer Inst. 2015 Apr 8;107(6):djv077. doi: 10.1093/jnci/djv077. Print 2015 Jun. J Natl Cancer Inst. 2015. PMID: 25855725 Free article.
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G. Hergueta-Redondo M, et al. Oncotarget. 2016 Aug 30;7(35):56295-56308. doi: 10.18632/oncotarget.10787. Oncotarget. 2016. PMID: 27462779 Free PMC article.
Cancer network activity associated with therapeutic response and synergism.
Serra-Musach J, Mateo F, Capdevila-Busquets E, de Garibay GR, Zhang X, Guha R, Thomas CJ, Grueso J, Villanueva A, Jaeger S, Heyn H, Vizoso M, Pérez H, Cordero A, Gonzalez-Suarez E, Esteller M, Moreno-Bueno G, Tjärnberg A, Lázaro C, Serra V, Arribas J, Benson M, Gustafsson M, Ferrer M, Aloy P, Pujana MÀ. Serra-Musach J, et al. Genome Med. 2016 Aug 24;8(1):88. doi: 10.1186/s13073-016-0340-x. Genome Med. 2016. PMID: 27553366 Free PMC article.
152 results